Loading...Loading...Healthcare insurance firm Humana Inc HUM cut its fiscal 2023 earnings outlook as the costs of members’ care exceeded its expectations.The company expects 2023 adjusted earnings to be $26.09 a share, per an SEC filing Thursday. Humana had earlier forecast at least $28.25 a share versus the consensus of $28.30.“Due to the recency and significance of the latest emerging trends, the company was unable to offset the entirety of the higher than anticipated medical costs that continued to increase through the end of the fourth quarter,” the company said in the filing.During the third quarter earnings call, the company projected that the increased medical utilization observed in its Medicare Advantage business would persist for the remainder of the year. Also Read: After Dropping Humana Acquisition Attempt Cigna In Talks To Sell Medicare Advantage Business Amid Competition.The actual results for the fourth quarter confirmed a further rise in Medicare Advantage medical costs, driven by unexpectedly high inpatient utilization, especially in November and December. .

正在加载。。。正在加载。。。医疗保险公司Humana Inc HUM下调了2023财年的盈利前景，因为会员的医疗费用超出了预期。根据周四提交给美国证券交易委员会的文件，该公司预计2023年调整后的每股收益为26.09美元。Humana此前曾预测每股至少28.25美元，而普遍预期为28.30美元。该公司在文件中表示：“由于最新新兴趋势的出现和重要性，该公司无法抵消截至第四季度末持续增加的高于预期的医疗费用。”。在第三季度财报电话会议期间，该公司预计其Medicare Advantage业务中观察到的医疗利用率增加将持续到今年剩余时间。另请阅读：在放弃Humana收购尝试后，信诺在竞争中出售Medicare Advantage业务。第四季度的实际结果证实，医疗保险优势医疗成本进一步上升，这是由于住院患者利用率出乎意料地高，尤其是在11月和12月。。

Additionally, non-inpatient trends, particularly in physician services, outpatient surgeries, and supplemental benefits, saw a notable increase in claims data for November and December, received in December and January, respectively. The elevated cost trends are anticipated to lead to a fourth-quarter 2023 Adjusted Insurance segment benefit ratio of approximately 91.4%, deviating from the company’s initial expectation of 89.5%. The full-year Adjusted Insurance segment benefit ratio is also expected to be around 88%, contrasting with the company’s previous projection of 87.5%.Loading...Loading...2024 Guidance.

此外，非住院趋势，特别是在医生服务、门诊手术和补充福利方面，分别在12月和1月收到的11月和12月的索赔数据显着增加。预计成本上升趋势将导致2023年第四季度调整后的保险部门收益率约为91.4%，偏离公司最初的预期89.5%。全年调整后的保险部门收益率预计也将在88%左右，而公司之前的预测为87.5%。加载……加载……2024指导。

Following the annual election period (AEP), Humana has adjusted its projection for individual Medicare Advantage (MA) growth, anticipating an increase of around 100,000 members by December 31, 2024, up 1.8% from its membership as of December 31, 2023 of approximately 5.4 million.

在年度选举期（AEP）之后，Humana调整了其对个人医疗保险优势（MA）增长的预测，预计到2024年12月31日将增加约100000名成员，比截至2023年12月31日约540万名成员增加1.8%。

This revision contrasts with the company’s earlier forecast of achieving ‘at or slightly above industry average growth.’

此次修订与该公司此前预测的“达到或略高于行业平均增长率”形成对比

The outlook for 2024 is influenced by Humana’s balanced pricing strategy, resulting in a reduced share of the overall industry growth.

2024年的前景受到Humana平衡定价策略的影响，导致整个行业增长的份额下降。

Although the overall AEP sales volume met expectations, a higher proportion was driven by plan changes among existing members, leading to lower-than-expected new member sales.

尽管AEP的总销售额达到了预期，但现有成员的计划变化推动了更高的比例，导致新成员销售额低于预期。

Despite the increased plan change activity, Humana experienced slightly higher attrition during the AEP than initially anticipated.

尽管计划变更活动有所增加，但Humana在AEP期间的损耗略高于最初的预期。

The actual AEP growth for the company stands at approximately 120,000 members, with an expected slight decline by year-end.

该公司的实际AEP增长率约为120000名成员，预计到年底将略有下降。

This decline is attributed to the more limited sales opportunities post-AEP and the anticipation of slightly higher attrition within its Dual Special Needs Plan offerings.

这一下降归因于AEP后销售机会更加有限，以及预计其双重特殊需求计划产品的损耗会略高。

This higher attrition is expected in the coming months as members lose dual eligible status due to the ongoing Medicaid redetermination process.

由于正在进行的医疗补助重新确定过程，会员失去双重资格，预计未来几个月会出现更高的流失率。

Investors have reacted to Humana’s weak guidance as the stock is down over 10%. Other players have also felt the pinch.The Cigna Group NYSE: CI) stock is down 3.07% at $299.00, with CVS Health Corp CVS stock trading 2.83% lower at $74.80 and UnitedHealth Group Inc UNH down 2.66% at $ 511.00 during the premarket trading.Price Action: HUM shares are down 12.20% at $393.00 during the premarket session on the last check Thursday.Photo via Wikimedia CommonsLoading...Loading....

由于Humana股价下跌超过10%，投资者对其疲软的指导做出了反应。其他球员也感受到了压力。信诺集团（纽约证券交易所：CI）股价下跌3.07%，至299.00美元，CVS Health Corp CVS股价下跌2.83%，至74.80美元，联合健康集团（UnitedHealth Group）UNH股价下跌2.66%，至511.00美元。价格走势：HUM股价在周四最后一次检查的上市前交易中下跌12.20%，至393.00美元。照片通过Wikimedia CommonLoading。。。正在加载。。。。